8-K: Xtant Medical Reports Strong Second Quarter Revenue Growth of 48%

Xtant Medical announced a 48% increase in revenue for the second quarter of 2024, alongside positive adjusted EBITDA.

Summary

• Xtant Medical reported a significant 48% increase in revenue for the second quarter of 2024, reaching $29.9 million, compared to $20.2 million in the same period last year.
• The company's gross margin improved slightly to 62.1%, a 50 basis point increase from 61.6% in the prior year quarter.
• Xtant Medical experienced a net loss of $3.9 million for the quarter, compared to a net loss of $2.2 million in the second quarter of 2023.
• Adjusted EBITDA was positive at $0.5 million, up from $0.1 million in the prior year quarter, marking the fifth consecutive quarter of positive adjusted EBITDA.
• The company reaffirmed its full-year 2024 revenue guidance of $116 million to $120 million, representing a 27% to 31% increase compared to 2023.
• A $5.0 million private placement was completed on August 7, 2024, to strengthen the balance sheet.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved gross margins, and positive adjusted EBITDA. The company's future outlook is also optimistic, with plans for new product launches and increased internal production. However, the net loss and increased operating expenses temper the overall sentiment slightly.

Positives

• The company achieved a substantial 48% year-over-year revenue growth in the second quarter.
• Gross margin saw a positive increase of 50 basis points.
• Xtant Medical reported its fifth consecutive quarter of positive adjusted EBITDA.
• The launch of new products and expansion of the distributor network are contributing to growth.
• The recent private placement has strengthened the company's balance sheet.
• The company is expecting further margin improvement and positive operating cash flow in the second half of 2024.

Negatives

• The company reported a net loss of $3.9 million for the second quarter, which is higher than the $2.2 million loss in the same quarter of the previous year.
• Operating expenses increased to $21.5 million, up from $13.9 million in the prior year quarter, due to increased commission and compensation expenses.
• Cash and cash equivalents decreased slightly from $5.7 million at the end of 2023 to $5.4 million as of June 30, 2024.

Risks

• The company faces lingering supply chain challenges, although they are being addressed through the launch of self-produced products.
• There are risks associated with integrating acquired businesses.
• The company is subject to risks related to future operating results and financial performance.
• There are risks associated with the company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers.
• The company is subject to risks associated with its recently announced private placement.
• There are risks associated with anticipated shortages of stem cells which will adversely affect future revenues.
• The company is subject to risks associated with its ability to implement successfully its future growth initiatives.
• The company is subject to risks associated with possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory.
• The company is subject to risks associated with the ability to remain competitive.
• The company is subject to risks associated with the ability to innovate, develop and introduce new products and the success of those products.
• The company is subject to risks associated with the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the company's dependence on key independent agents for a significant portion of its revenue.
• The company is subject to risks associated with the effect of labor and hospital staffing shortages on the company's business, operating results and financial condition, especially when they affect key markets.
• The company is subject to risks associated with the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions.
• The company is subject to risks associated with the effect of product sales mix changes on the company's financial results.
• The company is subject to risks associated with government and third-party coverage and reimbursement for company products.
• The company is subject to risks associated with the ability to obtain and maintain regulatory approvals and comply with government regulations.
• The company is subject to risks associated with the effect of product liability claims and other litigation to which the company may be subject.
• The company is subject to risks associated with the effect of product recalls and defects.
• The company is subject to risks associated with the ability to obtain and protect company intellectual property and proprietary rights and operate without infringing the rights of others.
• The company is subject to risks associated with the company's clinical trials.
• The company is subject to risks associated with international risks.
• The company is subject to risks associated with the ability to service company debt, comply with its debt covenants and access additional indebtedness.
• The company is subject to risks associated with the ability to obtain additional financing on favorable terms or at all.

Future Outlook

Xtant Medical expects additional new product launches, increased penetration within its distributor network, and an increase in internally produced products in the second half of 2024, which are expected to drive further margin improvement and generate positive operating cash flow. The company reaffirms its full-year 2024 revenue guidance of $116 million to $120 million.

Management Comments

• Sean Browne, President and CEO of Xtant Medical, stated, 'Our second quarter financial results illustrate the positive momentum that is building as we head into the second half of 2024.'
• Browne also noted, 'We enter the second half of the year with significant business momentum and, after our recently announced private placement, a stronger balance sheet to support our strategic growth plans.'

Industry Context

The medical technology industry is experiencing growth, and Xtant Medical's focus on spinal solutions aligns with the demand for advanced surgical treatments. The company's expansion through acquisitions and new product launches positions it to compete effectively in this market.

Comparison to Industry Standards

• Xtant Medical's 48% revenue growth significantly exceeds the average growth rate for medical device companies, which typically ranges from 5% to 15% annually.
• The company's gross margin of 62.1% is competitive with other medical device manufacturers, such as Medtronic and Stryker, which often report gross margins between 60% and 70%.
• While the company is reporting a net loss, the positive adjusted EBITDA indicates improving operational efficiency, which is a key metric for investors in the medical technology sector.
• The company's focus on internal production and new product launches is similar to strategies employed by other successful medical device companies to improve margins and drive growth.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and positive adjusted EBITDA favorably.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to new products and solutions.
• Suppliers may see increased demand for their products.
• Creditors may view the company's improved financial performance positively.

Next Steps

• The company plans to launch additional new products in the second half of 2024.
• Xtant Medical aims to increase penetration within its distributor network.
• The company intends to increase the number of internally produced products.
• Xtant Medical will host a webcast and conference call to discuss second quarter 2024 financial results on August 9, 2024.

Key Dates

Keywords

medical technology, spinal disorders, orthobiologics, spinal implants, revenue growth, adjusted EBITDA, private placement, allografts, distributors, IDN contracts